Clinical advances in painful and painless diabetic neuropathy

doi:10.16352/j.issn.1001-6325.2023.06.0985

Abstract

Abstract: Painful neuropathy is present in 13% to 35% of diabetic patients, and the reasons for the differential clinical manifestations of painful and painless diabetic neuropathy (DNP) in diabetic patients are unclear. This review focuses on the latest clinical advances. It is observed that gender, diabetes type, glycosylated hemoglobin, and blood lipid levels have certain predictive effects on painful DNP. Clinical attention should be paid to pain and paresthesia caused by small fiber neuropathy. Existing diagnostic Methods have limited differential effect, and active drug treatment is required after the diagnosis of painful DNP is confirmed. Further research on the pathogenesis of painful DNP is required in order to find new therapeutic target.

Key words: diabetic neuropathy, painful, painless

CLC Number:

R747.9

YU Zhuoying, YANG Jing, JIANG Ye, LI Min. Clinical advances in painful and painless diabetic neuropathy[J]. Basic & Clinical Medicine, 2023, 43(6): 985-989.

References 24

[1]	Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy[J]. Nat Rev Endocrinol,2021, 17: 400-420.
[2]	Truini A, Spallone V, Morganti R, et al. A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy[J].Pain,2018, 159: 2658-2666.
[3]	Abraham A, Barnett C, Katzberg HD, et al. Sex differences in neuropathic pain intensity in diabetes[J]. J Neurol Sci,2018, 388: 103-106.
[4]	Gylfadottir SS, Christensen DH, Nicolaisen SK, et al. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes[J]. Pain, 2020, 161: 574-583.
[5]	Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K[J].Diabetes Care,2011, 34: 2220-2224.
[6]	Jambart S, Ammache Z, Haddad F, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region[J]. J Int Med Res,2011, 39: 366-377.
[7]	Pai YW, Tang CL, Lin CH, et al Glycaemic control for painful diabetic peripheral neuropathy is more than fasting plasma glucose and glycated haemoglobin[J]. Diabetes Metab,2021, 47: 101158. doi: 10.1016/j.diabet.2020.04.004.
[8]	Ferdousi M, Azmi S, Kalteniece A, et al. Greater small nerve fibre damage in the skin and cornea of type 1 diabetic patients with painful compared to painless diabetic neuropathy[J].Eur J Neurol,2021, 28: 1745-1751.
[9]	Elsharkawy RE, Abdel Azim GS, Osman MA, et al. Peripheral polyneuropathy and cognitive impairment in type Ⅱ diabetes mellitus[J]. Neuropsychiatr Dis Treat,2021, 17: 627-635.
[10]	Lai YR, Cheng BC, Huang CC, et al. Correlation between kidney and peripheral nerve functions in type 2 diabetes[J]. QJM,2020, 113: 173-180.
[11]	Raputova J, Srotova I, Vlckova E, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study[J]. Pain,2017, 158: 2340-2353.
[12]	Pai YW, Lin CH, Lee IT, et al. Prevalence and biochemical risk factors of diabetic peripheral neuropathy with or without neuropathic pain in Taiwanese adults with type 2 diabetes mellitus[J]. Diabetes Metab Syndr,2018, 12: 111-116.
[13]	Mizokami-Stout KR, Li Z, Foster NC, et al. The contemporary prevalence of diabetic neuropathy in type 1 diabetes: findings from the T1D exchange[J].Diabetes Care,2020, 43: 806-812.
[14]	Jende JME, Groener JB, Rother C, et al. Association of serum cholesterol levels with peripheral nerve damage in patients with type 2 diabetes[J]. JAMA Netw Open,2019, 2: e194798. doi: 10.1001/jamanetworkopen.2019.4798.
[15]	Alam U, Petropoulos IN, Ponirakis G, et al. Vitamin D deficiency is associated with painful diabetic neuropathy[J]. Diabetes Metab Res Rev,2021, 37: e3361. doi: 10.1002/dmrr.3361.
[16]	Davoudi M, Rezaei P, Rajaeiramsheh F, et al. Predicting the quality of life based on pain dimensions and psychi-atric symptoms in patients with painful diabetic neuropa-thy: a cross-sectional prevalence study in Iranian patients[J]. Health Qual Life Outcomes,2021, 19: 49. doi: 10.1186/s12955-021-01697-w.
[17]	Kalteniece A, Ferdousi M, Azmi S, et al. Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy[J]. Sci Rep,2020, 10: 3371. doi: 10.1038/s41598-020-60422-7.
[18]	Themistocleous AC, Ramirez JD, Shillo PR, et al. The pain in neuropathy study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy[J].Pain,2016, 157: 1132-1145.
[19]	Karlsson P, Provitera V, Caporaso G, et al. Increased peptidergic fibers as a potential cutaneous marker of pain in diabetic small fiber neuropathy[J]. Pain,2021, 162: 778-786.
[20]	Gylfadottir SS, Itani M, Kristensen AG, et al. Analysis of macrophages and peptidergic fibers in the skin of patients with painful diabetic polyneuropathy[J]. Neurol Neuroimmunol Neuroinflamm,2021, 9:e1111.doi:10.1212/NXI.0000000000001111.
[21]	Puttgen S, Bonhof GJ, Strom A, et al. Augmented corneal nerve fiber branching in painful compared with painless diabetic neuropathy[J]. J Clin Endocrinol Metab,2019, 104: 6220-6228.
[22]	Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropathy: current and developmental drugs[J]. Drugs, 2020, 80: 363-384.
[23]	Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: A randomized clinical trial[J]. JAMA Neurol,2021, 78: 687-698.
[24]	Falowski S, Pope JE, Raza A. Early US experience with stimulation of the dorsal root ganglia for the treatment of peripheral neuropathy in the lower extremities: A multicenter retrospective case series[J]. Neuromodulation,2019, 22: 96-100.